Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

Shares of DexCom Inc. rallied 3.79% to $73.38 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 1.08% to 5,675.29 and the Dow ...

DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz.

As the U.S. stock market navigates a period of mixed performance, with major indices like the Dow Jones and S&P 500 experiencing fluctuations amid economic uncertainties and tariff concerns, investors ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments.

The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

Dexcom, a medical device manufacturer that develops continuous glucose monitoring systems, received a warning letter from the FDA regarding manufacturing processes at its facilities in San Diego and ...

DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.